Patents Assigned to TONIX Pharmaceuticals Holding Corp
  • Labeled oxytocin and method of manufacture and use
    Patent number: 11970554
    Abstract: Disclosed are 13N-oxytocin molecules, methods of manufacture of 13N-oxytocin molecules and methods of use of 13N-oxytocin molecules in the determination of the distribution and kinetics of 13N-oxytocin molecules after craniofacial or other application methods.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: April 30, 2024
    Assignees: TONIX PHARMACEUTICALS HOLDING CORP., AARHUS UNIVERSITY
    Inventors: Steen Jakobsen, Michael Winterdahl, Erik Nguyen Nielsen, David C. Yeomans, Dean Carson
  • ANALOGS OF CYCLOBENZAPRINE AND AMITRYPTILENE
    Publication number: 20230149348
    Abstract: The present invention relates to cyclobenzaprine analogs and amitriptyline analogs, including deuterated forms useful for treatment or prevention of symptoms associated with post-traumatic stress disorder.
    Type: Application
    Filed: December 5, 2022
    Publication date: May 18, 2023
    Applicant: TONIX PHARMACEUTICALS HOLDING CORP
    Inventors: Seth Lederman, Darryl Rideout, Greg Sullivan
  • Radio-protective and chemo-protective substituted thiols
    Patent number: 11566032
    Abstract: The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methylamino)methyl)propane-1-thiol. The compounds of this disclosure also relate to The use of these compounds as radio— and chemo—protectors is also described.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: January 31, 2023
    Assignees: TONIX PHARMACEUTICALS, INC., TONIX PHARMACEUTICALS HOLDING CORP.
    Inventors: Philip S. Schein, Darryl C. Rideout
  • Analogs of cyclobenzaprine and amitriptyline
    Patent number: 11517557
    Abstract: The present invention relates to cyclobenzaprine analogs and amitriptyline analogs, including deuterated forms useful for treatment or prevention of symptoms associated with post-traumatic stress disorder.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: December 6, 2022
    Assignee: TONIX PHARMACEUTICALS HOLDING CORP.
    Inventors: Seth Lederman, Darryl Rideout, Greg Sullivan
  • Magnesium-containing oxytocin formulations and methods of use
    Patent number: 11389473
    Abstract: Disclosed are magnesium-containing oxytocin peptide formulations or compositions comprising an oxytocin peptide and a magnesium salt that produces synergistic analgesia when used in treating pain. Also disclosed are methods for the treatment of pain (such as migraine headache) comprising co-administration of an oxytocin peptide and a magnesium salt.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: July 19, 2022
    Assignee: Tonix Pharmaceuticals Holding Corp.
    Inventors: David C. Yeomans, Dean Carson, Ramachandran Thirucote
  • INHIBITORS OF CD40-CD154 BINDING
    Publication number: 20220185785
    Abstract: Disclosed herein are compounds including pharmaceutically acceptable salts, esters, prodrugs, hydrates and tautomers thereof which modulate the interactions of CD-40-CD40L. The compounds are useful for treating, ameliorating or preventing an autoimmune disease, inflammatory disease, or other immune-related disease in a patient in need of treatment.
    Type: Application
    Filed: April 13, 2020
    Publication date: June 16, 2022
    Applicant: TONIX PHARMACEUTICALS HOLDING CORP
    Inventors: Darryl RIDEOUT, Seth LEDERMAN
  • ANALOGS OF CYCLOBENZAPRINE AND AMITRYPTILENE
    Publication number: 20200230104
    Abstract: The present invention relates to cyclobenzaprine analogs useful for treatment or prevention of symptoms associated with post-traumatic stress disorder.
    Type: Application
    Filed: July 13, 2018
    Publication date: July 23, 2020
    Applicant: Tonix Pharmaceuticals Holding Corp
    Inventors: Seth Lederman, Darryl Rideout, Greg Sullivan
  • TREATMENT FOR COCAINE ADDICTION
    Publication number: 20130165511
    Abstract: A novel pharmaceutical composition is provided for the control of stimulant effects, in particular treatment of cocaine addiction, or further to treatment of both cocaine and alcohol dependency, including simultaneous therapeutic dose application or a single dose of a combined therapeutically effective composition of disulfiram and selegiline compounds or pharmaceutically acceptable non-toxic salt thereof.
    Type: Application
    Filed: August 31, 2011
    Publication date: June 27, 2013
    Applicant: TONIX Pharmaceuticals Holding Corp
    Inventors: Seth Lederman, Herbert Harris